Skip to main content
. 2021 Nov 24;298(1):101448. doi: 10.1016/j.jbc.2021.101448

Figure 5.

Figure 5

Keap1-KD attenuates USP10-KD/dopamine-induced cell death.A, SH-SY5Y cells were transfected with USP10-siRNA (siUSP10-2), Keap1-siRNA (siKeap1-5, 6, or 7) or control (siNT) using Lipofectamine RNAiMAX. Cells were treated with 0.4 mM dopamine or DMSO for 8 h. Whole cell lysates were characterized by Western blotting using the indicated antibodies. B, SH-SY5Y cells were transfected with USP10-siRNA (siUSP10-2), Keap1-siRNA (siKeap1-5, 6 or 7), or control (siNT) using Lipofectamine RNAiMAX. Cells were then treated with 0.2 to 0.4 mM dopamine or DMSO for 12 h and with CCK-8 solution for 1 h, and the cell viability was measured with the CCK-8 kit by measuring the absorbance (485 nm) of the culture medium. The ratio of the absorbance of the cells to that of the control cells (siNT) treated with DMSO was presented as the mean and SD of three samples. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗∗p  <  0.0001. USP10, ubiquitin-specific protease 10.